CNA3103 (LGR5-targeted, Autologous CAR-T Cells)

Name: CNA3103 (LGR5-targeted, Autologous CAR-T Cells) in Colorectal Cancer Metastatic
Creator: Floatz
License: https://terminal.floatz.ai/terms

Colorectal Cancer Metastatic

Carina Biotech LimitedCell therapyPhase 1/2Active

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 65/ 100

Competitive context

64 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / Sponsor	Phase	Rating
Binimetinib Pierre Fabre Medicament	Phase 3	BB
Irinotecan Oncolytics Biotech	Phase 4	BB
Aflibercept Sanofi	Phase 3	BB
Inno-206 Northwell Health	Phase 4	B
Durvalumab University of Iowa	Phase 2	B

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →